Prokidney (PROK) EBITDA (2021 - 2026)

Prokidney (PROK) has reported EBITDA for 6 consecutive years, with -$48.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 21.82% year-over-year to -$48.4 million in Q2 2026; TTM through Jun 2026 was -$177.2 million, a 2.44% increase from a year earlier, with the FY2025 full-year figure at -$165.0 million, up 10.16% from the prior year.
• EBITDA was -$48.4 million for Q2 2026 at Prokidney, down from -$44.9 million in the prior quarter.
• Over five years, EBITDA peaked at -$20.7 million in Q2 2022 and troughed at -$66.5 million in Q1 2022.
• A 5-year average of -$41.5 million and a median of -$41.1 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 14501997.9% in 2022 and soared 38.5% in 2023, its largest moves.
• Over 5 years, EBITDA stood at -$30.2 million in 2022, then gained by 19.93% to -$24.2 million in 2023, then slumped by 113.02% to -$51.6 million in 2024, then grew by 12.02% to -$45.4 million in 2025, then fell by 6.62% to -$48.4 million in 2026.
• The last three EBITDA figures came in at -$48.4 million (Q2 2026), -$44.9 million (Q1 2026), and -$45.4 million (Q4 2025), per Business Quant data.